 price
slow clap tma put
thesi updat team deserv massiv hat tip
speed ramp capac meet pandem head
sens may catch bad break earn
hold rel well covid test offset
market alreadi look everi compani
base valuat thu get
credit big year vs whose ep
significantli said still catch big bump
covid test stock ran face
past coupl day one peer broke news
tee covid panther tma high
throughput version test use across
system world-wide tma expect mm rev
partial off-set declin rest busi
see waterfal chart pace estim
mm covid test off-set legaci
busi declin math net almost equal rest
year key question remain covid test
sustain dont think tests/wk
year point case declin serolog test
account major test global also
believ test paradigm like includ form
flu/covid panel similar mani syndrom test panel
avail biomerieux biocarti etc
addit test like move closer poc offer like
abt idnow test could prerequisit
go limit seat eleven madison park either way
deceler off-set
rest busi come back growth like end
back start year bring us back
origin point catch bad break kind
multipl put stock pt
trade similar multipl slight discount
debat merit comp bottom line
struggl stretch valuat base
holx ep growth profil thu slow draw
stay sidelin better entri point reiter
rate rais pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
org sale apr ex covid test sale
similar declin base busi
surgic hardest hit st
bh skelet apr
apr
servic off-set capit sale declin
strength intern
covid could signific posit off-set demand high larg manuf capac could
dx apr ex covid assay b/c core women health essay hold
gener mm
hope busi get back normal
still signific offset
driven
organ growth feb
pace anoth beat rais
molecular incl mm covid assay ex covid
surgic jan feb
bh surgic also dd
reduc op ex reduc run-rat mm
plan get tests/week start late may
test readi ship next week
asp slightli
add mm revenue
leverag cash equiv
boost capital-expenditure covid manuf
suspend repo repurchas mm mm
typic place /year scale
anyth resourc molecular
high interest pcr across eu us creat tremend oppo
soon bh come back doctor offic
bh order posit could slower come back
covid test asp littl global
adjac move closer poc
decentr area lab run test
poc abl run test local geographi near drive-through
want capac fall
hard know test ran per day
optim aptima swab provid custom complet packag incl vial
sale intrauterin portfolio
feel good surgic busi
believ better product sale team
assum new covid test cannib core panther platform
busi diversifi capit equip lag recoveri wouldnt back next
fusion panther instal base
valuat methodolog base mix discount cash flow analysi rel valuat multipl
failur execut cyno weigh sentiment multipl higher expect declin mammographi
margin expans thesi doesnt play due higher invest turn around busi
articl articl
time dissemin april pm et
analyst luke sergott daniel markowitz cindi ding vijay kumar primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
